Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

By S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K. Lee, M. de Wit and 20 more. New England Journal of Medicine, 2017

2,617 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bc10125127431bb867bf7de2d808510bb1d5e8d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok

Citations in the corpus

• The future of cancer immunotherapy: microenvironment-targeting combinations (2020, methodology): “For example, in the PACIFIC trial, over 700 patients with non-small cell lung cancer were randomized to the PD-1 inhibitor durvalumab versus placebo after definitive chemoradiotherapy, and the patients who received ICI demonstrated improved clinical outcomes.(139) Trials of ICI and radiation are enr”